Ranbaxy Laboratories Ltd. is a research based International pharmaceutical company with its headquarters in India. It manufactures a range of high quality, affordable generic drugs. The company has manufacturing facilities in around 9 countries. It has strong presence in around 49
countries, products available in around 125 countries globally. It has dedicated workforce of about 10,500 employees representing 51 different countries.

Ranbaxy was established in 1961 and went public in the year 1973. It has global sales of US $1340 million for the year ended on 31st December, 2006. It has the largest market in USA (sales appx. US $380 million); then come Europe and BRICS (Brazil, Russia, India, China, South Africa).
Ranbaxy has a strong R&D competence that provides a sustainable competitive advantage to the company. It has scholarly pool of about 1100 scientists, engaged in out-of-box researches. Ranbaxy spends over 7% of its sales on R&D. Licensing of once-a-day Ciprofloxacin formulation, using NDDS (Novel Drug Delivery System) on a worldwide basis, was the first international success for the company.

Ranbaxy is focused on Discovery and development of drugs on anti-infectives, urology, respiratory/ inflammatory and metabolic diseases.

Top ten molecules of the company are:

  • Co-amoxiclav
  • Amoxicillin
  • Ciprofloxacin
  • Cephalexin
  • Simvastatin
  • Isotretinoin
  • Cefaclor
  • Clarithromycin
  • Cefpodoxime Proxetil
  • Ketorolac Tromethamine

Corporate office:
Plot 90, Sector 32,
Gurgaon -122001 (Haryana), INDIA
Ph: +91-124-4135000
Fax: +91-124-4135001

Web site: www.ranbaxy.com

Quarterly Results of Ranbaxy

Quarterly Results (Rs.in Millions)
Dec 2006(3 rd quarter) Sept 2006(2nd quarter) Dec 2005(3 rd quarter)
Sales Turnover 10159.8 11035.9 8820.4
Other Income 294.8 -190.9 250.4
Total Income 10454.6 10845 9070.8
Total Expenditure 8410.9 9064.5 8248.7
Operating Profit 2043.7 1780.5 822.1
Interest 136 176 67.9
Gross Profit 1907.7 1604.5 754.2
Depreciation 254.6 292.1 269.6
Tax 262.4 113.3 -4.3

*Source: economictimes.indiatimes.com

Quarterly Results (in %)
% Change Over Sep 2006 % Change Over Dec 2005
Sales Turnover -7.94 15.19
Other Income 0 17.73
Total Income -3.6 15.26
Total Expenditure -7.21 1.97
Operating Profit 14.78 148.6
Interest -22.73 100.29
Gross Profit 18.9 152.94
Depreciation -12.84 -5.56
Tax
Reported PAT 42.91 41.92

*Source: economictimes.indiatimes.com

Annual Results of Ranbaxy

Annual Unaudited Results (Rs. in Millions)
(12 Months) (12 Months) % Changes
Sales Turnover 39735.60 34901.30 13.85
Other Income 795.7 2096.60 -62.05
Total Income 40531.30 36997.90 9.55
Total Expenditure 34141.10 34243.70 -0.3
Operating Profit 6390.20 2754.20 132.02
Interest 581 264.1 119.99
Gross Profit 5809.20 2490.10 133.29
Depreciation 1117.60 1013.30 10.29
Tax 601.1 -223.4 -369.07
Reported PAT 3864.50 2237.00 72.75

*Source: economictimes.indiatimes.com